Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
about
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationOccurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era.Management of viral hepatitis B.Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Late hepatic allograft dysfunction.A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.Liver transplantation in the UK.Hepatitis B: progress in the last 15 years.Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era.Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature.Developments in liver transplantation.Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapyA Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic ChemotherapyReview article: Nucleoside analogues for the treatment of chronic hepatitis B.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.Review article: hepatitis B and liver transplantation.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.The management of chronic hepatitis B in Asian Americans.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Treatment of recurrent hepatitis B infection in liver transplant recipients.Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance.A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.Lamivudine for hepatitis B after liver transplantation.Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B.A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection.Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results.Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation.Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.
P2860
Q26784241-F1054DD5-ADA7-42A2-970C-2D1402116DE5Q33183104-141316DA-C182-4936-B1C9-2801D994260AQ33207885-7AE7A355-DD8C-49A6-A693-E59C638171D7Q33959006-8416F416-8F18-4A7B-852D-05787F48236CQ34012806-64796307-1A46-4B57-8FCF-F8EF8A276655Q34382067-6E7119E5-76E3-4336-87EA-7373404745FFQ34426400-75D98CB9-EF22-4886-96E8-F8794F4A9CF3Q34499694-4E4515FF-B19C-462D-8E6C-4CBF5409A505Q34512132-BA8C12D5-04C9-4330-B992-6AB242A3E2AFQ34936238-EDA85AED-2E9E-46DA-B6F5-A13F53ACACE7Q35076630-9B729BED-6FD8-48B6-8C7F-C8338EB416BAQ35110095-D0B50301-14C5-4F6F-9730-9584924568F3Q35596527-F91FBDCC-D9D6-43E2-AB2B-E64957891559Q35597892-F6810E9C-FFB4-4998-ACE0-7BCFC987567FQ35677319-889AA4B2-0023-462C-A8AC-2576F8CE8EF8Q35987869-620EE07F-E6DA-422A-845E-3C31F9E73329Q36028324-42B79EAF-9E9B-46D9-8B85-690A3E2D2F68Q36447557-080CEFA6-DED8-4EC8-9C15-7DCC01649FABQ37760897-9D61557E-E78B-481B-ABCB-66F94B2BF517Q37936321-52A3AA34-8C98-40FD-B19C-4C3DC4A461E4Q38665203-FA34E3D7-C85E-4E75-8D00-8E30C685A985Q40629253-1DAD167B-5A0B-4100-8DD1-CC21604EEAFFQ42247961-2BDDD059-0D72-4264-8E2D-CFA1B135F5B3Q43666866-E74AE1BF-18FA-41FB-BC6E-20D97A98B5DBQ43666869-13EB7EEF-66F5-47F3-B429-3659EF4982B9Q43762367-3C7EB53C-ACBD-4761-8C91-42EF02573462Q43988921-84720804-6784-4CD4-ACED-9D8C292E9F1CQ44018025-66C3351A-A7BC-4CA2-9582-947F50443A90Q44048412-B94D7AE8-FB07-420F-8EE0-0AAE8D86A83FQ44124730-40EBC442-250D-4BD5-983E-E0DEFC645FC9Q44165111-8C762CED-411D-4A5C-A4FE-2EB632B134A9Q44217548-B58F8BB6-5AC3-477F-BAF6-BC07E3D42482Q44254904-3D23990A-EAC0-46EA-9CC4-059E0600441EQ44277485-1AB66E99-ABA0-4AF1-A80B-64E53D59AFECQ44355905-05DE417A-B84D-4B38-B377-01CEE8D47393Q44895107-BC9E0A28-DE3B-4C7D-A186-7D21463C60EBQ45227673-7951FBB2-6A6E-47E3-8A2D-62EA839A53ABQ45250862-F49A2975-D9FF-4727-9D99-FFDFEF10E71DQ45411000-E8DCA860-CC58-43F2-AD7A-45378A34F5E0Q51877261-80480CFE-4715-4ABF-8D0F-7E389B3E18CD
P2860
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Outcome of lamivudine resistan ...... the liver transplant recipient
@ast
Outcome of lamivudine resistan ...... the liver transplant recipient
@en
Outcome of lamivudine resistan ...... the liver transplant recipient
@nl
type
label
Outcome of lamivudine resistan ...... the liver transplant recipient
@ast
Outcome of lamivudine resistan ...... the liver transplant recipient
@en
Outcome of lamivudine resistan ...... the liver transplant recipient
@nl
prefLabel
Outcome of lamivudine resistan ...... the liver transplant recipient
@ast
Outcome of lamivudine resistan ...... the liver transplant recipient
@en
Outcome of lamivudine resistan ...... the liver transplant recipient
@nl
P2093
P2860
P356
P1433
P1476
Outcome of lamivudine resistan ...... the liver transplant recipient
@en
P2093
D Ratcliffe
K O'Donnell
P2860
P304
P356
10.1136/GUT.46.1.107
P407
P577
2000-01-01T00:00:00Z